SCHEMBL280523

SCHEMBL280523

B[C@H]1CC[C@@](F)(CO)O1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12060944 0.73
SCHEMBL3414852 0.70
SCHEMBL12060723 0.65 DPP4 (0.31)
SCHEMBL12060724 0.65
SCHEMBL24371224 0.63
SCHEMBL20434443 0.63
SCHEMBL3461873 0.62
SCHEMBL14215558 0.62
SCHEMBL13271077 0.59
SCHEMBL18016490 0.58

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2981542-B1 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS LLC (US) 2021-09-15 EP disclosed
US-20120157514-A1 OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS Regulus Therapeutics Inc. (US) 2012-06-21 US disclosed
US-8133876-B2 Oligomeric compounds and compositions for use in modulation of small non-coding RNAs Regulus Therapeutics Inc. (US) 2012-03-13 US disclosed
US-8110558-B2 Oligomeric compounds and compositions for use in modulation of small non-coding RNAS Regulus Therapeutics Inc. (US) 2012-02-07 US disclosed
US-20120029049-A1 Antisense Modulation of Superoxide Dismutase 1, Soluble Expression Isis Corporation (US) 2012-02-02 US disclosed
US-20110224277-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2011-09-15 US disclosed
US-20110171730-A1 Conjugates For Use In Hepatocyte Free Uptake Assays ISIS PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
US-7897582-B2 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein ISIS PHARMACEUTICALS, INC. (US) 2011-03-01 US disclosed
US-7812149-B2 Comprises nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents ISIS PHARMACEUTICALS, INC. (US) 2010-10-12 US disclosed
US-7713944-B2 Oligomers comprising activated disulfides which bind to plasma proteins and their use for delivery to cells ISIS PHARMACEUTICALS, INC. (US) 2010-05-11 US disclosed
US-20090291906-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2009-11-26 US disclosed
US-20090291907-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2009-11-26 US disclosed
US-20090286969-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2009-11-19 US disclosed
US-20090203132-A1 PYRROLIDINYL GROUPS FOR ATTACHING CONJUGATES TO OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. 2009-08-13 US disclosed
US-20080027019-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN ISIS PHARMACEUTICALS, INC. (US) 2008-01-31 US disclosed